Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Shaping the future: advancing HR-NMIBC management beyond BCG

EMUC 2025

13 - 16 Nov 2025

Published: 15 Nov 2025

Views: 64

Rating:

Save

Dr Laura Mertens, Dr Marco Moschini and Prof Evanguelos Xylinas

Interactive industry seminar from EMUC25 in Prague, featuring:

Welcome and introductions - Dr Laura Mertens
A journey through challenge: managing a case of HR-NMIBC - Dr Marco Moschini
Navigating complexity: decision-making in HR-NMIBC after BCG - All faculty; moderated by Dr Laura Mertens
Broadening the therapeutic horizon: advancing care in HR-NMIBC - Prof Evanguelos Xylinas
Final thoughts and close - Dr Laura Mertens

To read the guidelines summary click here

This industry symposium is funded and organised by Johnson & Johnson in EMEA and is intended for healthcare professionals only.

Not available in Czechia

Related Videos

Driving optimal patient outcomes with personalised strategies in mHSPC

Prof Christian Schwentner, Prof Athanasios Papatsoris and Prof Gert Attard

Driving optimal patient outcomes with personalised strategies in mHSPC ( Prof Christian Schwentner, Prof Athanasios Papatsoris and Prof Gert Attard )

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich

Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )

(Bio) Markers and milestones at the crossroads of mHSPC care 

Dr Miguel Ramírez-Backhaus, Prof Jozefina Casuscelli, Prof Gerhardt Attard

(Bio) Markers and milestones at the crossroads of mHSPC care  ( Dr Miguel Ramírez-Backhaus, Prof Jozefina Casuscelli, Prof Gerhardt Attard )

Challenging the status quo: Unlocking new horizons for patients with HR-NMIBC...

Prof Bernardo Hererra Imbroda and Dr Géraldine Pignot

Challenging the status quo: Unlocking new horizons for patients with HR-NMIBC after BCG treatment ( Prof Bernardo Hererra Imbroda and Dr Géraldine Pignot )

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini

New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible...

Dr Sarah Psutka - University of Washington, Seattle, USA

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy ( Dr Sarah Psutka - University of Washington, Seattle, USA )

Challenges of managing patients with NMIBC: from risk stratification to...

Dr Benjamin Pradère, Dr Bernadett Szabados, Prof Shahrokh Shariat

Challenges of managing patients with NMIBC: from risk stratification to treatment and beyond ( Dr Benjamin Pradère, Dr Bernadett Szabados, Prof Shahrokh Shariat )

ASCO GU 2025: Latest updates in mRCC

Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...

ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )

Precision oncology: Optimising therapeutic strategies in mHSPC and mCRPC

Prof. Gert Attard, Prof. Dr. Dr. Philipp Mandel, Dr. Lynda Corrigan

Precision oncology: Optimising therapeutic strategies in mHSPC and mCRPC ( Prof. Gert Attard, Prof. Dr. Dr. Philipp Mandel, Dr. Lynda Corrigan )

More from ecancer